Kapitalrendite von co.don AG ist -86.35%
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.